Needham Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and doubles the price target from $8 to $16.
May 14, 2024 | 9:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham's analyst Serge Belanger reaffirmed a Buy rating on Verrica Pharmaceuticals and increased the price target from $8 to $16, indicating a strong positive outlook on the company's future performance.
The doubling of the price target by a reputable analyst suggests a strong conviction in the company's growth prospects or underlying value, which could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100